Uncategorized
Ocular Therapeutix begins phase 2 clinical trial for sustained release dexamethasone
Ocular Therapeutix enrolled the first patient in a phase 2 clinical trial to evaluate the safety and efficacy of sustained-release dexamethasone to treat inflammatory dry eye disease, according to a press release.A one-time bioresorbable intracanalicular plug will release dexamethasone to the ocular surface for up to 30 days.